Dis-Chem Pharmacies Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Rui Morais
Chief executive officer
R10.6m
Total compensation
| CEO salary percentage | 71.05% |
| CEO tenure | 2.9yrs |
| CEO ownership | n/a |
| Management average tenure | 3yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Analysis Article • Apr 07
Here's Why We Think Dis-Chem Pharmacies (JSE:DCP) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Feb 13
Why You Should Care About Dis-Chem Pharmacies' (JSE:DCP) Strong Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...Analysis Article • Nov 22
Dis-Chem Pharmacies (JSE:DCP) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Nov 07
Dis-Chem Pharmacies (JSE:DCP) Is Paying Out A Larger Dividend Than Last Year
Dis-Chem Pharmacies Limited ( JSE:DCP ) has announced that it will be increasing its dividend from last year's...Analysis Article • Oct 23
Pinning Down Dis-Chem Pharmacies Limited's (JSE:DCP) P/E Is Difficult Right Now
When close to half the companies in South Africa have price-to-earnings ratios (or "P/E's") below 9x, you may consider...Analysis Article • Sep 05
Dis-Chem Pharmacies (JSE:DCP) Knows How To Allocate Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Aug 14
Dis-Chem Pharmacies (JSE:DCP) Seems To Use Debt Quite Sensibly
JSE:DCP 1 Year Share Price vs Fair Value Explore Dis-Chem Pharmacies's Fair Values from the Community and select yours...Analysis Article • Jul 17
With Dis-Chem Pharmacies Limited (JSE:DCP) It Looks Like You'll Get What You Pay For
Dis-Chem Pharmacies Limited's ( JSE:DCP ) price-to-earnings (or "P/E") ratio of 22.9x might make it look like a strong...Analysis Article • May 27
Dis-Chem Pharmacies (JSE:DCP) Is Aiming To Keep Up Its Impressive Returns
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
New Narrative • Mar 13
Expanding Into Underrepresented Areas And Digital Health Will Strengthen Market Position In ZA Retail
Strategic expansion and enhanced cost management are driving revenue and net margin growth, with significant investment in new property and underrepresented areas.Analysis Article • Feb 22
Dis-Chem Pharmacies (JSE:DCP) Knows How To Allocate Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...Analysis Article • Jan 22
Dis-Chem Pharmacies Limited's (JSE:DCP) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 28.3x Dis-Chem Pharmacies Limited ( JSE:DCP ) may be sending very bearish...Analysis Article • Nov 27
Is Dis-Chem Pharmacies (JSE:DCP) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Nov 10
Shareholders Are Optimistic That Dis-Chem Pharmacies (JSE:DCP) Will Multiply In Value
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...Analysis Article • Aug 21
These 4 Measures Indicate That Dis-Chem Pharmacies (JSE:DCP) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • Jun 06
Shareholders Should Be Pleased With Dis-Chem Pharmacies Limited's (JSE:DCP) Price
When close to half the companies in South Africa have price-to-earnings ratios (or "P/E's") below 8x, you may consider...Analysis Article • Apr 17
Dis-Chem Pharmacies (JSE:DCP) Will Be Hoping To Turn Its Returns On Capital Around
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysis Article • Feb 26
Dis-Chem Pharmacies (JSE:DCP) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Dec 30
Dis-Chem Pharmacies (JSE:DCP) Might Be Having Difficulty Using Its Capital Effectively
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Sep 07
If EPS Growth Is Important To You, Dis-Chem Pharmacies (JSE:DCP) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Aug 16
Here's Why Dis-Chem Pharmacies (JSE:DCP) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysis Article • Jul 31
Dis-Chem Pharmacies (JSE:DCP) Will Want To Turn Around Its Return Trends
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Analysis Article • May 09
Is Now The Time To Put Dis-Chem Pharmacies (JSE:DCP) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Mar 29
There Are Reasons To Feel Uneasy About Dis-Chem Pharmacies' (JSE:DCP) Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Jan 14
Is Now The Time To Put Dis-Chem Pharmacies (JSE:DCP) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Nov 04
Returns On Capital At Dis-Chem Pharmacies (JSE:DCP) Paint A Concerning Picture
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...Analysis Article • Oct 04
Dis-Chem Pharmacies Limited (JSE:DCP) Shares Could Be 24% Below Their Intrinsic Value Estimate
In this article we are going to estimate the intrinsic value of Dis-Chem Pharmacies Limited ( JSE:DCP ) by taking the...Analysis Article • Sep 01
We Ran A Stock Scan For Earnings Growth And Dis-Chem Pharmacies (JSE:DCP) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Jul 04
Some Investors May Be Worried About Dis-Chem Pharmacies' (JSE:DCP) Returns On Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...Analysis Article • Jun 21
A Look At The Fair Value Of Dis-Chem Pharmacies Limited (JSE:DCP)
How far off is Dis-Chem Pharmacies Limited ( JSE:DCP ) from its intrinsic value? Using the most recent financial data...Analysis Article • Jun 08
Dis-Chem Pharmacies (JSE:DCP) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • May 25
The Dis-Chem Pharmacies Limited (JSE:DCP) Yearly Results Are Out And Analysts Have Published New Forecasts
Investors in Dis-Chem Pharmacies Limited ( JSE:DCP ) had a good week, as its shares rose 2.8% to close at R35.15...Analysis Article • Feb 23
Is Dis-Chem Pharmacies (JSE:DCP) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Feb 08
Dis-Chem Pharmacies Limited's (JSE:DCP) Price In Tune With Earnings
Dis-Chem Pharmacies Limited's ( JSE:DCP ) price-to-earnings (or "P/E") ratio of 41.7x might make it look like a strong...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Feb 28 2026 | R11m | R8m | R979m |
| Nov 30 2025 | n/a | n/a | R1b |
| Aug 31 2025 | n/a | n/a | R1b |
| May 31 2025 | n/a | n/a | R1b |
| Feb 28 2025 | R16m | R13m | R1b |
| Nov 30 2024 | n/a | n/a | R1b |
| Aug 31 2024 | n/a | n/a | R1b |
| May 31 2024 | n/a | n/a | R1b |
| Feb 29 2024 | R17m | R12m | R984m |
| Nov 30 2023 | n/a | n/a | R942m |
| Aug 31 2023 | n/a | n/a | R899m |
| May 31 2023 | n/a | n/a | R949m |
| Feb 28 2023 | R18m | R12m | R1b |
| Nov 30 2022 | n/a | n/a | R1b |
| Aug 31 2022 | n/a | n/a | R1b |
| May 31 2022 | n/a | n/a | R946m |
| Feb 28 2022 | R14m | R11m | R853m |
| Nov 30 2021 | n/a | n/a | R815m |
| Aug 31 2021 | n/a | n/a | R776m |
| May 31 2021 | n/a | n/a | R722m |
| Feb 28 2021 | R6m | R6m | R669m |
| Nov 30 2020 | n/a | n/a | R655m |
| Aug 31 2020 | n/a | n/a | R641m |
| May 31 2020 | n/a | n/a | R620m |
| Feb 29 2020 | R6m | R6m | R598m |
Compensation vs Market: Rui's total compensation ($USD640.51K) is below average for companies of similar size in the ZA market ($USD1.61M).
Compensation vs Earnings: Rui's compensation has been consistent with company performance over the past year.
CEO
Rui Morais (42 yo)
2.9yrs
Tenure
R10,605,000
Compensation
Mr. Rui Manuel Morais, CA(SA) has been the Chief Executive Officer at Dis-Chem Pharmacies Limited since July 01, 2023 and its Executive Director since August 13, 2012. He served as Chief Financial Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.9yrs | R10.61m | no data | |
| CFO & Executive Director | 2.9yrs | R9.23m | no data | |
| Executive Director | 3yrs | R10.07m | no data | |
| Executive Director | 3.9yrs | R22.91m | 3.3% ZAR 926.3m | |
| Prescribed Officer | no data | R10.94m | no data | |
| Company Secretary | 5.3yrs | no data | no data | |
| Prescribed Officer | no data | R5.36m | no data | |
| Prescribed Officer | no data | R5.68m | no data |
3.0yrs
Average Tenure
69yo
Average Age
Experienced Management: DCP's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 13.8yrs | R10.61m | no data | |
| CFO & Executive Director | 2.9yrs | R9.23m | no data | |
| Executive Director | 21.1yrs | R10.07m | no data | |
| Executive Director | 3.9yrs | R22.91m | 3.3% ZAR 926.3m | |
| Independent Non-Executive Chairman | 9.7yrs | R937.00k | no data | |
| Independent Non-Executive Director | 9.7yrs | R962.00k | 0.014% ZAR 3.9m | |
| Independent Non-Executive Director | 9.7yrs | R608.00k | no data | |
| Non-Independent Non-Executive Director | 3.9yrs | R19.36m | 0.68% ZAR 191.4m | |
| Independent Non-Executive Director | 5.4yrs | R3.68m | no data | |
| Non-Independent Non Executive Director | 4.6yrs | R849.00k | no data | |
| Independent Non-Executive Director | 3.9yrs | R1.18m | no data |
5.4yrs
Average Tenure
57yo
Average Age
Experienced Board: DCP's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/07 06:34 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/02/28 |
| Annual Earnings | 2026/02/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dis-Chem Pharmacies Limited is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rendani Magalela | Absa Bank Limited |
| Daniel Dias | Arqaam Capital Research Offshore S.A.L. |
| Michael de Nobrega | Avior Capital Markets |